Established in 1998, went public in May 2012, Dongcheng Biochemicals Co.,Ltd has developed into an enterprise group which combines pharmaceutical R&D, production, marketing and capital operation together,across field of biochemical API, chemical synthetic drugs and modern Chinese Medicines. At present, DCB owns four subsidiaries, including – YanTai DongCheng Beifang Pharmaceuticals Co.,Ltd, YanTai DongCheng Dayang Pharmaceuticals Co.,Ltd , Yinan DongCheng Don gyuan Bioengineering Co.,Ltd and DongCheng Biochemicals (USA),Inc, also sets up R&D branch in Beijing and Shanghai. Currently, the number of DCB employee is reaching 1000 .
DCB now is one of the biggest biochemical API manufacturers in China, With leading production technology, reliable product quality and excellent international qualification background, the company’s Heparin sodium and Chondroitin Sulfate products have hold important place in global market . Currently 90% of DCB API products are for export, thanks to company’s well-established global sales network, our API products have been exported to more than fifty countries and regions, including USA,Germany,Austria, Japan etc. Meanwhile, with strategic development approach of “Organic Growth, Coupled with M&A and integration”, DCB group also focuses on development of finished preparation, currently DCB’s finished preparations cover therapeutic area of Cardiovascular, oncology, orthopaedics, and anti-infection etc.